Its the promise of stem cell medicine: Someday soon, clinics will rebuild diseased or broken hearts, kidneys, pancreases or blood by growing and reprogramming human cells, then adding them back to the bodies of the patients they came from.
If only it were that easy.
After two decades of human stem cell research, researchers have learned how to create what appear to be reasonably functional versions of several types of cells, first using genetic tricks to turn cells back to an uncommitted state and then molding them into the type of cell needed say, an insulin-producing cell or a particular kind of nerve cell. And many early clinical trials of stem cell medicine have shown genuinely promising results.
But applying such techniques en masse simply wont be practical, because the lengthy processes for extracting and preparing an individuals own cells wont scale up, some scientists say.
For one thing, everyones cells will behave a little bit differently, says Lonnie Shea, a biomedical engineer at the University of Michigan, Ann Arbor. And then theres the bottom line. It is beyond too expensive, says Douglas Melton, cofounder of the Harvard Stem Cell Institute, a network of more than 1,000 Harvard-affiliated scientists.
Instead, increasingly, labs around the world are seeking to design off-the-shelf cell therapies using universal donor cells that are genetically altered to avoid the many-armed responses of the immune system against foreign tissues. Scientists want to create a suite of such cells tailored for specific tissue repairs: universal muscle cells, universal skin cells or universal insulin-producing pancreatic beta cells.
The big dream is a cell that would be like a pill, which could go into any patient, says Melton, who called for a global push to realize this vision at a stem cell meeting in Los Angeles in June.
This trend in regenerative medicine parallels events in cancer medicine. Personalized treatments that genetically reengineer the T cells of patients with certain blood cancers are often effective, but such therapies cost hundreds of thousands of dollars per patient and it can take years for manufacturing to get up and running. Cancer researchers around the world now are working to create off-the-shelf versions.
Its all part of a broader effort to bring the rapidly advancing power of genetic engineering more deeply into regenerative medicine, says pediatric hematologist Leslie Kean of Harvard Medical School, director of the Stem Cell Transplant Center at Boston Childrens Hospital. This is not just science fiction anymore.
Our bodies normally are quick to reject any cell that isnt our own. While that response often can be overridden by drugs designed to suppress the immune system, these medicines bring significant risks and side effects. So the goal is for universal donor cells to be hypoimmunogenic able to hold off the immune systems many lines of defense without requiring immunosuppression.
In one development, scientists at the University of California, San Francisco and colleagues reported in Nature Biotechnology in February that theyd created hypoimmunogenic mouse and human cells through a several-step process. The starting ingredients were iPS cells (induced pluripotent stem cells). These are adult cells engineered to lose their specific cell identities so they can once again become many different cell types, a condition known as pluripotency. By tinkering with a few genes in these iPS cells, the researchers could produce heart cells, muscle cells and endothelial cells (which line the inside of blood vessels). All showed stealth behavior to the two main branches of the immune system adaptive and innate when transplanted into mice.
To accomplish this, the lab did two things. First, it knocked out several molecules of the human leukocyte antigen (HLA) system components of the adaptive immune system. The proteins of this system normally stud the surface of cells and signal otherness to T cells if they dont match with the bodys.
If you take that away, the T cells cannot recognize a cell as foreign, and you dont see T cell activation anymore, says Sonja Schrepfer, the studys senior author and head of UCSFs Transplant and Stem Cell Immunobiology Lab and a founding scientist for the Seattle-headquartered startup company Sana Biotechnology.
This image shows insulin-producing beta cells that were made from stem cells. Cells like this could one day be transplanted into people with type I diabetes, but they would need to be protected by immune-suppressing drugs or encapsulation. Cost and complexity will remain huge barriers for most therapies based on pluripotent stem cells until scientists can create cells that dont trigger immune responses.
CREDIT: MELTON LAB / HARVARD UNIVERSITY
But removing HLA activity still leaves other, innate aspects of the immune system intact. For example, natural killer cells will normally wipe out cells that no longer make certain HLA proteins. To solve that problem, Schrepfer and colleagues tapped into a long-studied phenomenon of pregnancy known as fetal-maternal tolerance: why the mothers immune system will not reject a fetus even though half the proteins are from the father.
The fetus, it turns out, avoids attack by boosting or tamping down the activity of various genes, including one called CD47. And by increasing activity of CD47 as well as removing some HLA molecules, Schrepfers team got the results they wanted.
Less is more in modifying iPS cells, Schrepfer says. Editing of each molecule has risks, so you want to find the minimum combination you need to achieve hypoimmunity.
Another example of preliminary success with hypoimmunogenic human cells came from a team within the Harvard Stem Cell Institute network, led by stem cell researcher Chad Cowan, now with Sana Biotechnology.
Like the UCSF group, the scientists lowered the activity of certain HLA genes and boosted activity of the CD47 gene in pluripotent cells. But they also increased the production of a different class of HLA molecules: ones that help the fetus dodge the mothers immune system.
And they added another step, taking lessons learned from cancer cells that evade the immune system. Through genetic tinkering, the team boosted the production of a protein called PD-L1 that these tumor cells use to turn away T cells.
The complex set of genetic modifications, reported in the journal PNAS in April, significantly dialed down immune reaction when the cells were infused in mice. T cell responses were blunted, and attacks by natural killer cells and macrophages (another class of immune cell) were minimal.
As research on universal donor cell therapies moves forward, one of the biggest concerns is that these cells which are made pluripotent again, then turned into the required adult tissues, using imperfect gene editing tools may generate tumors. To garner FDA approval, cell lines will have to be extensively vetted for any signs of danger, but there are worries that no process can provide complete protection.
There are always theoretical concerns about cells retaining some measure of pluripotency, which would mean that they wouldnt have a signal to stop growing, says Kean of Boston Childrens Hospital. Still, she says, theres been a ton of research to suggest that really wont be an issue with the iPS-derived cells that are being produced now; a lot of those potential risks have been engineered out.
Labs also can add an insurance policy in the form of suicide genes, a technique long studied in clinical trials for cancer, in which cells are engineered to kill themselves if exposed to a certain chemical compound. If the cell starts to do anything thats troublesome, youll take a pill like doxycycline, and itll kill those cells and only those cells, Melton says.
Teratomas tumors comprising a variety of tissue types such as hair, bone and teeth are a particular worry in the use of pluripotent stem cells in therapies, including for regulatory agencies, says stem cell researcher Juan Domnguez-Bendala of the Diabetes Research Institute in the University of Miami Miller School of Medicine. Nobody can be certain of what may happen when you start transplanting thousands of patients. One single case of a teratoma may set the field back for years.
And so Domnguez-Bendala, who is developing insulin-producing pancreatic beta cells to treat type I diabetes, has generated human pluripotent stem cells with two kinds of suicide genes. One of them is designed to spring to life in any implanted cell that transforms into something other than a beta cell. The other can be activated in cells that show molecular signs of forming a tumor.
The immune system is there 24/7, always knocking at the door.
Reporting in the journal Stem Cell Reports in March, Domnguez-Bendala and colleagues found that they could largely prevent tumor formation when the cells were transplanted in mice, and any that slipped through the net could be destroyed. Our strategy allows us to selectively preserve the cells of interest while killing off everything else, he says, and it can be easily adapted to any specific cell.
Tumors are not the only risk, though. The excitement about universal donor cells is tempered with caution because the immune system has such a full bag of tricks, says Shea, who coauthored an overview of the technology in the Annual Review of Biomedical Engineering. The immune system is there 24/7, always knocking at the door. If you can do something to protect the cells, thats a great start, but it has to be on, 24/7 it cant weaken.
Its unclear, he says, how the immune system as a whole will react if certain cells in the body are chronically making immune-suppressing molecules. Perhaps the universal donor cells initially will engraft and function well, but problems may crop up over time. Maybe the grafted cells will eventually be destroyed. Or what if those cells are infected with a virus will the immune system be able to eliminate it?
Given such concerns, many immunologists believe that it may be necessary to retrain the immune system rather than just find ways for cells to dodge its bullets.
Keans lab, for example, is looking for a combination of drugs that can be administered for a limited time to reset the immune system so that the transplant is tolerated without interrupting normal protective immunity.
Different types of cells may require different degrees of immune stealthiness, Kean points out. Insulin-producing beta cells ideally will last a lifetime, while heart muscle cells may not need to persist for long if their job is just to offer temporary support while the heart repairs itself.
Generating universal donor cells is not the only approach to off-the-shelf regenerative medicine, and this concept may be combined with other therapeutic techniques.
Shea, for instance, works with immunologist Haval Shirwan of the University of Louisville School of Medicine on a method that transplants insulin-producing cells on a microporous scaffold that is coated with molecules designed to blunt T cell attacks. If a short regimen of an immunosuppressant drug is given at the same time, these transplanted cells survive well in lab mice.
Other labs take an even more radical approach they want to develop drugs that trigger cells in the patients own body to reprogram themselves and repair their own tissues. Sana and the biotech startup Oxstem in Oxford, England, are both pursuing this approach.
Overall, researchers say its an exciting time in off-the-shelf regenerative medicine though with plenty of work still to do.
So far, Melton notes, only a handful of functionally mature cells have been created from stem cells, including beta cells, heart muscle cells and certain kinds of skin, retinal and nerve cells. And its still years before universal donor cells will be tested in humans.
But he also stresses the potential of the quest. The promise of this kind of regenerative medicine is not to just find new treatments, he says, but to literally find cures for diseases.
Continue reading here:
Now in development: off-the-shelf stem cells - Knowable Magazine
- New human-mouse chimera is the most human yet - Livescience.com - May 30th, 2020
- Animal Stem Cell Therapy Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026| - Jewish Life News - May 30th, 2020
- The Secret Behind Mike Tysons Transformation Will Shock You! - Essentially Sports - May 30th, 2020
- Research at MDI Biological Laboratory explores novel pathways of regeneration and tumorigenesis - Bangor Daily News - May 30th, 2020
- Stem Cell Equipment Market Size By Type, Application, Region and Forecasts, 2026| Chart, Worthington Industries, Cesca Therapeutics, Shengjie... - May 30th, 2020
- How Coronavirus is Impacting Market Research on Canine Stem Cell Therapy Market 2019 and Analysis to 2028 - News Distinct - May 30th, 2020
- Stem Cell Source Market Size Analysis and Growth (2020-2025) - 3rd Watch News - May 30th, 2020
- Stem Cell Cartilage Regeneration Market: Analysis of Prevailing Trends In The Parent Market 2026 - Cole of Duty - May 30th, 2020
- Cell Isolation Market Detailed Analysis 2019-2024: Beckman Coulter, Becton, Dickinson and Company, GE Healthcare, Merck KgaA, Miltenyi Biotec and... - May 30th, 2020
- Coronavirus (COVID-19) Impact On Global Stem Cell Concentration System Market 2020 Analysis By Top Key Players | EmCyte, Zimmer Biomet, Argos... - May 30th, 2020
- (2020-2026) Biologics Safety Testing Market Research, Growth Opportunities, Analysis and Forecasts Report - 3rd Watch News - May 30th, 2020
- Stem Cell Banking Outsourcing Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - News Distinct - May 30th, 2020
- Assessing the Fallout From the Coronavirus Pandemic New Report on the Stem Cell Therapy Market 2019-2026 - 3rd Watch News - May 25th, 2020
- Stem Cell Therapy Market Size, Analysis, Top Key Vendors, Industry Growth, Opportunity and Forecast by 2026 - WaterCloud News - May 25th, 2020
- Assessing the Fallout From the Coronavirus Pandemic Cell Isolation Technology Market Globally Expected to Drive Growth through 2026 - Jewish Life... - May 25th, 2020
- Stem Cell Alopecia Treatment Market Size, Analysis, Top Key Vendors, Industry Growth, Opportunity and Forecast by 2026 - WaterCloud News - May 25th, 2020
- Expected A Drastic Growth In Stem Cell Banking Market Key Insights Based On Source, Service Type, Application - 3rd Watch News - May 24th, 2020
- Covid 19 Pandemic: STEM CELL BANKING Market 2020 Statistics and Research Analysis Released in Latest Report - 3rd Watch News - May 24th, 2020
- Slump in Production of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Amidst Covid-19 Outbreak to Diminish Prospects of Sales - Bulletin... - May 24th, 2020
- Potential Impact of COVID-19 on Cell Separation Technologies Market to Show Outstanding Growth by 2025 Profiling Global Players Industry... - May 24th, 2020
- The impact of the coronavirus on the Stem Cell and Primary Cell Culture Medium Market 2020 -Global Industry Analysis By Trends, Size, Share, Company... - May 24th, 2020
- Bone Marrow Processing Systems Market Quantitative Market Analysis, Current and Future Trends the COVID-19 - Cole of Duty - May 24th, 2020
- Coronavirus (COVID-19) Business Impact Stem Cell Banking Market : In-depth Analysis to Understand the Competitive Outlook of the Global Industry with... - May 24th, 2020
- How Coronavirus is Impacting In-Depth Cell Separation Market Analysis for 2020 and Beyond - 3rd Watch News - May 24th, 2020
- HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's disease treatment - PRNewswire - May 22nd, 2020
- Global Stem Cells Group Announces the Launch of its New Division VITA NOVAS - PR Web - May 22nd, 2020
- Not All Cancer Research Money Is Going Away During COVID University of Chicago Receives $10-million Gift For Cell Therapy - SurvivorNet - May 22nd, 2020
- Scientists to study how lungs respond to worm infections - UC Riverside - May 22nd, 2020
- Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - News Distinct - May 22nd, 2020
- Stem Cell Assay Market Growing Demand, Overview and Business Outlook to 2027 | Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent... - May 22nd, 2020
- Global Stem Cells Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2026 - Cole of Duty - May 22nd, 2020
- Plant Stem Cell For Cosmetics Market New Investments Expected To Boost The Demand By 2027 - News Distinct - May 22nd, 2020
- Californians for Stem Cell Research, Treatments & Cures - May 21st, 2020
- UAE Press: In the race to find a COVID-19 cure, leaders must not forget other diseases in need of research funds - WAM EN - May 21st, 2020
- Stem Cell Drugs Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of Duty - May 21st, 2020
- BOOMING NEWS: COVID-19 IMPACT ON Stem Cells Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and... - May 21st, 2020
- Global Stem Cell Media Market Competitive Dynamics and Industry Outlook 2025 - 3rd Watch News - May 21st, 2020
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of... - May 21st, 2020
- The Impact of the Coronavirus on the Nerve Repair and Regeneration Market Growth, Trends and Competitive Landscape | P&S Intelligence - Cole of Duty - May 21st, 2020
- The impact of the coronavirus on the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Size, Analysis, and Forecast Report 2019-2023 Cole... - May 21st, 2020
- Warning about stem cell treatments and COVID-19 - 10News - May 20th, 2020
- Research frozen by COVID-19 begins to thaw - The Age - May 20th, 2020
- Animal Stem Cell Therapy Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of Duty - May 20th, 2020
- Stem Cell Alopecia Treatment Market 2020 Global Overview, Growth, Size, Opportunities, Trends, Leading Company Analysis and Forecast to 2026 - Cole of... - May 20th, 2020
- New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair - SciTechDaily - May 19th, 2020
- Unproven stem cell products are being peddled as COVID-19 'therapies,' U of M researcher reports - MinnPost - May 19th, 2020
- Clinical Trial Shows Topical Stem Cell Treatment Leads to Hair Regrowth in Common Type of Baldness - Technology Networks - May 19th, 2020
- Tyson, Ronaldo, and more sports stars who use stem cell treatment costing up to 15,000 to speed up healing - The Sun - May 19th, 2020
- Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data - PRNewswire - May 19th, 2020
- COVID-19 Impact on Human Embryonic Stem Cell Market 2020 Regional Outlook, Latest Trend, Share Analysis, Growth, Application and Forecast to 2027 -... - May 19th, 2020
- Critical window for re-infection with HIV after stem cell transplantation - BioNews - May 19th, 2020
- COVID 19 PANDEMIC: Cancer Stem Cell Market Expert Guide to Boost the Industry in Market Share - Cole of Duty - May 19th, 2020
- Stem Cell And Platelet Rich Plasma (PRP) Alopecia Therapies Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 -... - May 19th, 2020
- Stem Cell Concentration System Market - Growth, Trends, and Forecast (2020 - 20 - News by aeresearch - May 19th, 2020
- How Coronavirus is Impacting Cell Isolation Technology Market Growth Opportunity and Industry Revenue Analysis by Major Players, 2019-2026 3w Market... - May 19th, 2020
- 'No silver bullet': Investors cautioned as market surges on vaccine hopes - Sydney Morning Herald - May 19th, 2020
- Hematopoietic Stem Cell Transplantation Market Research, Growth Opportunities, Key Players, Outlook and Forecasts Report 2020-2028 - The Billings... - May 19th, 2020
- Stem Cell Cartilage Regeneration Market Brief Analysis and Application, Growth by 2026 - Cole of Duty - May 17th, 2020
- Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Review Study,Indepth Analysis is Available in Recent Research Report During... - May 17th, 2020
- Stem Cell Banking Market Analysis Focusing on the Key Issues Surrounding the Growth of the Industry and Further Develop Opportunities - Bandera County... - May 17th, 2020
- Stem Cell Banking Market - Need for Improved Regenerative Medication and Anatomy - BioSpace - May 16th, 2020
- Millions of Mature Human Cells Blood, Eye and Liver Cells Grown In a Mouse Embryo - SciTechDaily - May 16th, 2020
- Analysis on Impact of COVID19-Global Mycoplasma Testing Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and ATCC | Technavio... - May 16th, 2020
- Stem Cell Alopecia Treatment Market Research Report 2020 By Size, Share, Trends, Analysis and Forecast to 2026 - Cole of Duty - May 16th, 2020
- Covid-19 Pandemic Cancer Stem Cell Therapy Market Overview and Competitive Landscape 2020 to 2025 - Cole of Duty - May 16th, 2020
- Global Stem Cell Therapy Market Size, Growth, Trends and Forecast 2020-2025 - Cole of Duty - May 16th, 2020
- FDA Approves Qinlock for Patients with Pretreated, Advanced GIST - Curetoday.com - May 16th, 2020
- Longevity and Anti-senescence Therapy Market Projected to Experience Major Revenue Boost During the Forecast Period Between 2020-2026 | Covid-19... - May 16th, 2020
- Stem Cell Assay Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Bandera County Courier - May 16th, 2020
- A Method for Assessing the Role of Long Non-protein Coding RNAs - Technology Networks - May 16th, 2020
- One year on, Capricor's stem cell therapy appears to help DMD patients in small study, but investors balk at the data - Endpoints News - May 14th, 2020
- QurAlis Hauls In $42M to Move New ALS Therapies Into Human Testing - Xconomy - May 14th, 2020
- Umbilical Cord Blood (UCB) Stem Cell Industry Growth Forecast Analysis Manufacturers, Regions, Type and Application to 2026 - Express Journal - May 14th, 2020
- Animal Stem Cell Therapy Market Forecast 2020-2025, Latest Trends and Opportunities - ZZReport - May 14th, 2020
- Stem Cell Source Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 14th, 2020
- Global Mesenchymal Stem Cells Market 2020 with (Covid-19) Impact Research by Top Manufacturers, Industry Growth, Regional Analysis and Forecast by... - May 14th, 2020
- Stem Cell Banking Storage Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 14th, 2020
- Stem Cell And Platelet Rich Plasma Prp Alopecia Therapies Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of... - May 14th, 2020
- Proactive and tech-driven approach helps UAE, South Korea's fight against COVID-19 - WAM EN - May 14th, 2020
- Umbilical Cord Blood (UCB) Stem Cell Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 14th, 2020